Results 51 to 60 of about 1,927 (159)

HIV postnatal prophylaxis and infant feeding policies vary across Europe: results of a Penta survey

HIV Medicine, Volume 26, Issue 2, Page 207-217, February 2025.
Abstract Objectives This survey was conducted to describe current European postnatal prophylaxis (PNP) and infant feeding policies with the aim of informing future harmonized guidelines. Methods A total of 32 senior clinicians with relevant expertise, working in 20 countries within the European Region, were invited to complete a REDCap questionnaire ...
Georgina Fernandes, Elizabeth Chappell, Tessa Goetghebuer, Christian R. Kahlert, Santa Ansone, Stefania Bernardi, Guido Castelli Gattinara, Elena Chiappini, Catherine Dollfus, Pierre Frange, Bridget Freyne, Luisa Galli, Vania Giacomet, Galia Grisaru‐Soen, Christoph Königs, Hermione Lyall, Magdalena Marczynska, Mariana Mardarescu, Lars Naver, Tim Niehues, Antoni Noguera‐Julian, Kim Stol, Alla Volokha, Steven B. Welch, Claire Thorne, Alasdair Bamford   +25 more
wiley   +1 more source

Selective and rapid determination of raltegravir in human plasma by liquid chromatography–tandem mass spectrometry in the negative ionization mode

Journal of Pharmaceutical Analysis, 2015
A selective and rapid high-performance liquid chromatography–tandem mass spectrometry method was developed and validated for the quantification of raltegravir using raltegravir-d3 as an internal standard (IS).
Ajay Gupta, Swati Guttikar, Priyanka A. Shah, Gajendra Solanki, Pranav S. Shrivastav, Mallika Sanyal   +5 more
doaj  

Effectiveness, safety, and patient‐reported outcomes of emtricitabine/tenofovir alafenamide‐based regimens for the treatment of HIV‐1 infection: Final 24‐month results from the prospective German TAFNES cohort study

HIV Medicine, Volume 26, Issue 2, Page 239-251, February 2025.
Abstract Background Tenofovir alafenamide (TAF) was introduced in the European Union in 2015 as a novel prodrug of tenofovir showing similar efficacy in clinical trials and a more favorable safety profile than tenofovir disoproxil fumarate (TDF). The German TAFNES cohort study (2016–2019) was conducted to generate real‐world evidence. Methods Treatment‐
Christoph Stephan, Christoph D. Spinner, Ansgar Rieke, Stefan Christensen, Stefan Mauss, Sandra Schreiber, Boris Albuquerque, Marion Heinzkill, Heribert Ramroth, Hans‐Jürgen Stellbrink   +9 more
wiley   +1 more source

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection

Infection and Drug Resistance, 2010
Lisa M Chirch, Roy T SteigbigelDivision of Infectious Diseases, Department of Medicine, Stony Brook University Medical Center, Stony Brook, New York, USAAbstract: Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is the first available agent in a ...
Lisa M Chirch, Roy T Steigbigel
doaj  

Modern antiretroviral regimens

Медицинский совет, 2016
The article presents the results of major international studies (STARTMRK, ACTG A5257, SPRING 2, the SINGLE and FLAMINGO), which convincingly demonstrated the effectiveness and safety of drugs from the group of integrase inhibitors (raltegravir and ...
A. V. Kravchenko
doaj   +1 more source

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV

CPT: Pharmacometrics & Systems Pharmacology, 2021
Once‐daily two 600 mg tablets (1200 mg q.d.) raltegravir offers an easier treatment option compared to the twice‐daily regimen of one 400 mg tablet. No pharmacokinetic, efficacy, or safety data of the 1200 mg q.d.
Vera E. Bukkems, Teun M. Post, Angela P. Colbers, David M. Burger, Elin M. Svensson   +4 more
doaj   +1 more source

In vitro and patient studies with platelets to explore off‐target cardiovascular effects of integrase inhibitors

HIV Medicine, Volume 26, Issue 2, Page 285-294, February 2025.
Abstract Introduction People with HIV currently face a tenfold higher risk of developing cardiovascular disease (CVD) than those without HIV. Studies have shown various off‐target effects of antiretroviral treatment (ART) on the cardiovascular system, but little is known about the effects of currently used integrase strand transfer inhibitors (INSTIs ...
R. Keniyopoullos, A. A. Khawaja, M. Boffito, M. Emerson   +3 more
wiley   +1 more source

A global review of national guidelines of post‐exposure prophylaxis for the prevention of HIV

Journal of the International AIDS Society, Volume 28, Issue 1, January 2025.
Abstract Introduction The World Health Organization (WHO) recommends the use of antiretroviral drugs as post‐exposure prophylaxis (PEP) for preventing HIV acquisition for occupational and non‐occupational exposures. To inform the development of global WHO recommendations on PEP, we reviewed national guidelines of PEP for their recommendations.
Marcus Maisano, Daniel Tran, Virginia Macdonald, Rachel C. Baggaley, Nathan Ford, Cheryl C. Johnson, Ying Zhang, Jason J. Ong   +7 more
wiley   +1 more source

Characterization of Binding of Raltegravir to Plasma Proteins [PDF]

Antimicrobial Agents and Chemotherapy, 2013
ABSTRACT The objective of this study was to characterize raltegravir (RAL) binding to albumin and alpha-1-acid glycoprotein (AAG). Unbound and bound RAL were separated by ultrafiltration. The association constant ( K a ) was estimated by a graphical method.
Caroline Barau, Valérie Furlan, Yazdan Yazdanpanah, Jean-Michel Molina, Catherine Fagard, Anne-Marie Taburet, Aurélie Barrail-Tran   +6 more
openaire   +3 more sources

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens

Терапевтический архив, 2010
The paper gives the results of the largest international studies demonstrating the efficacy and safety of Raltegravir as part of antiretroviral treatment (ARVT) regimens in both patients starting therapy (STARTMRK study) and those pretreated with ...
Aleksey Viktorovich Kravchenko, A V Kravchenko   +1 more
doaj